Skip to Content

Glyxambi Approval History

FDA Approved: Yes (First approved January 30, 2015)
Brand name: Glyxambi
Generic name: empagliflozin and linagliptin
Dosage form: Tablets
Company: Boehringer Ingelheim Pharmaceuticals, Inc.
Treatment for: Diabetes, Type 2

Glyxambi (empagliflozin and linagliptin) is a sodium glucose co-transporter-2 (SGLT2) inhibitor and dipeptidyl peptidase-4 (DPP-4) inhibitor combination for the treatment of adults with type 2 diabetes.

Development History and FDA Approval Process for Glyxambi

DateArticle
Feb  2, 2015Approval FDA Approves Glyxambi (empagliflozin and linagliptin) for Type 2 Diabetes
Apr 14, 2014Boehringer Ingelheim and Eli Lilly Announce NDA Filing for Empagliflozin and Linagliptin Combination

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Hide